Lisata Therapeutics Q2 2024 net loss $5.0M; ASCEND Phase 2b top-line data expected Q4 2024

LISATA THERAPEUTICS, INC.

2024-Q2 EPS reported -$1.26

Net loss $5.0M in Q2 2024 vs $4.0M in Q2 2023; operating expenses down 19.7% to $5.5M.
Cash & equivalents $38.3M; funding into early 2026 covering all active trials to data milestones.
Phase 2b ASCEND trial (certepetide + chemo in mPDAC) top-line results from 95-patient Cohort A on track for Q4 2024.
BOLSTER Phase 2a in 1L cholangiocarcinoma fully enrolled ahead of plan; topline data mid-2025; 2L cohort added.
Certepetide received U.S. FDA Orphan Drug and Rare Pediatric Disease designations for osteosarcoma in H1 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.